Angiogenesis imaging in man: A personal view from the pharmaceutical industry

British Journal of Radiology

Volumn 76, Issue SPEC. ISS. 1, 2003, Pages

  Dzik Jurasz, Andrzej ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANGIOGENESIS; ARTICLE; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; FINANCIAL MANAGEMENT; HUMAN; IMAGING; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TUMOR VASCULARIZATION;

DIAGNOSTIC IMAGING; DRUG DESIGN; DRUG INDUSTRY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 8844220408     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/42249357     Document Type: Article

References (3)

1. Riggs TL. Research and development costs for drugs. Lancet 2004;363:184.
2. Fixing the drugs pipeline. The Economist - Technology Quarterly 2004; 13th March:32-3.
3. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566-80.